CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Comparing Palliative Stereotactic Body Radiotherapy vs. Palliative Standard Radiotherapy in Patients with Advanced Head and Neck Cancer
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab or Botensilimab Alone vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
The CCTG Central Office will be closed on some dates during the holidays with partial staff coverage, there is also information on shipment of specimens for banking and kit supply and BARL holiday schedule. Web-based applications (i.e. MANGO, GCP) will still be available and regular business hours will resume on Thursday, January 2, 2020 at 8:30 am EST.
Next year is almost here and in 2020 CCTG will be marking our 40th anniversary! We would like to recognize this milestone and the hard work of our clinical trials network across Canada at an anniversary celebration during the 2020 CCTG Spring Meeting.
Event details to follow in the New Year - make sure to save the date and celebrate 40 years of clinical trial excellence.
About 32 percent of older, sicker patients enrolled on a leukemia clinical trial experienced serious side effects from a treatment that combined a chemotherapy and an immunotherapy drug, leading investigators to pause the trial and the U.S. Food and Drug Administration to eventually pull the combination from the current study. The study was presented by Dr. Annette Hay at the 61st American Society of Hematology (ASH) Annual Meeting the world’s largest conference devoted to blood diseases and blood cancers like lymphoma, the findings serve as both triumph and warning.
A Genetic, Risk-Stratified Randomized Phase II Study of Four Fludarabine/Antibody Combinations For Patients with Symptomatic Previously Untreated Chronic Lymphocytic Leukemia. This randomized phase II trial studies how well fludarabine (fludarabine phosphate) and rituximab with or without lenalidomide or cyclophosphamide work in treating patients with symptomatic chronic lymphocytic leukemia.
The MEC4 (Alliance A091201) trial, a Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma has permanently closed.
CCTG LY18, A Phase I Master Protocol of Novel Combination Therapy for Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma, has been centrally activated.
The purpose of this study is to find the highest dose of a new drug, in combination with standard drugs, which can be tolerated without causing very severe side effects. The study treatment is new agents in combination with R-GDP or an equivalent regimen.
The CX5 trial A Randomized Phase III Trial Comparing Radical Hysterectomy and Pelvic Node Dissection vs Simple Hysterectomy and Pelvic Node Dissection in Patients with Low-Risk Early Stage Cervical Cancer (SHAPE) has met its accrual goal and is now closed to further randomizations.
We are coming up to a big holiday for American families. Please expect closure of U.S. Operations offices and laboratories on Thursday, November 28nd for the U.S. Thanksgiving. If you are planning to ship specimens to the U.S., please plan accordingly. Also remember that many of our U.S. collegues take additional holidays for an extra long weekend.
Happy Thanksgiviing to our U.S friends!
